Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Robotic Surgical Procedures | 13 | 2024 | 172 | 4.300 |
Why?
|
| Nephrectomy | 6 | 2018 | 93 | 2.260 |
Why?
|
| Kidney Neoplasms | 7 | 2019 | 175 | 2.130 |
Why?
|
| Laparoscopy | 8 | 2018 | 492 | 2.080 |
Why?
|
| Prostatectomy | 6 | 2024 | 104 | 1.520 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2017 | 115 | 1.500 |
Why?
|
| Ureter | 3 | 2020 | 37 | 1.240 |
Why?
|
| Prostatic Hyperplasia | 4 | 2018 | 35 | 1.130 |
Why?
|
| Robotics | 2 | 2018 | 86 | 1.030 |
Why?
|
| Catheter Ablation | 3 | 2017 | 160 | 0.990 |
Why?
|
| Creatinine | 1 | 2024 | 136 | 0.820 |
Why?
|
| Electroporation | 3 | 2020 | 36 | 0.810 |
Why?
|
| Operative Time | 4 | 2018 | 94 | 0.750 |
Why?
|
| Ureteral Obstruction | 2 | 2024 | 27 | 0.680 |
Why?
|
| Kidney Calculi | 2 | 2023 | 34 | 0.660 |
Why?
|
| Urologic Surgical Procedures | 2 | 2018 | 46 | 0.650 |
Why?
|
| Ablation Techniques | 1 | 2020 | 26 | 0.650 |
Why?
|
| Kidney | 5 | 2024 | 455 | 0.630 |
Why?
|
| Kidney Diseases | 2 | 2017 | 178 | 0.580 |
Why?
|
| Endoscopy | 2 | 2018 | 92 | 0.550 |
Why?
|
| Renal Nutcracker Syndrome | 1 | 2017 | 1 | 0.530 |
Why?
|
| Gynecology | 1 | 2018 | 58 | 0.530 |
Why?
|
| Ureteroscopy | 2 | 2023 | 19 | 0.520 |
Why?
|
| Papaverine | 1 | 2017 | 7 | 0.520 |
Why?
|
| Spasm | 1 | 2017 | 10 | 0.520 |
Why?
|
| Surgeons | 2 | 2018 | 191 | 0.520 |
Why?
|
| Renal Artery | 1 | 2017 | 36 | 0.510 |
Why?
|
| Vasodilator Agents | 1 | 2017 | 70 | 0.500 |
Why?
|
| Obstetrics | 1 | 2018 | 91 | 0.500 |
Why?
|
| Sutures | 1 | 2016 | 40 | 0.470 |
Why?
|
| Students, Medical | 1 | 2018 | 265 | 0.440 |
Why?
|
| Stents | 2 | 2022 | 500 | 0.430 |
Why?
|
| Retrospective Studies | 10 | 2024 | 6936 | 0.420 |
Why?
|
| Humans | 28 | 2024 | 65490 | 0.410 |
Why?
|
| Ketorolac | 2 | 2024 | 13 | 0.400 |
Why?
|
| Male | 18 | 2024 | 31202 | 0.380 |
Why?
|
| Treatment Outcome | 10 | 2024 | 5809 | 0.360 |
Why?
|
| Quality Improvement | 1 | 2016 | 468 | 0.340 |
Why?
|
| Internship and Residency | 1 | 2018 | 803 | 0.320 |
Why?
|
| Middle Aged | 11 | 2024 | 18390 | 0.280 |
Why?
|
| Patient Positioning | 2 | 2018 | 52 | 0.260 |
Why?
|
| Postoperative Period | 2 | 2018 | 130 | 0.250 |
Why?
|
| Adult | 6 | 2024 | 17465 | 0.250 |
Why?
|
| Female | 12 | 2024 | 34208 | 0.240 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2024 | 202 | 0.230 |
Why?
|
| Aged | 9 | 2024 | 15058 | 0.220 |
Why?
|
| Narcotics | 3 | 2024 | 57 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2024 | 1659 | 0.210 |
Why?
|
| Ureterolithiasis | 1 | 2024 | 14 | 0.210 |
Why?
|
| Lithotripsy, Laser | 1 | 2023 | 5 | 0.200 |
Why?
|
| Swine | 2 | 2020 | 397 | 0.180 |
Why?
|
| Renal Colic | 1 | 2022 | 14 | 0.180 |
Why?
|
| Adipose Tissue | 1 | 2024 | 300 | 0.170 |
Why?
|
| Propensity Score | 2 | 2021 | 192 | 0.160 |
Why?
|
| Age Factors | 1 | 2024 | 1592 | 0.160 |
Why?
|
| Postoperative Complications | 2 | 2017 | 1334 | 0.150 |
Why?
|
| Intestines | 1 | 2020 | 182 | 0.150 |
Why?
|
| Length of Stay | 2 | 2024 | 828 | 0.150 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 1564 | 0.150 |
Why?
|
| Morcellation | 1 | 2018 | 1 | 0.150 |
Why?
|
| Prostatic Neoplasms | 2 | 2024 | 498 | 0.140 |
Why?
|
| Learning Curve | 1 | 2018 | 33 | 0.140 |
Why?
|
| Adenoma | 1 | 2018 | 70 | 0.140 |
Why?
|
| Preoperative Period | 1 | 2018 | 67 | 0.140 |
Why?
|
| Cystoscopy | 1 | 2018 | 17 | 0.140 |
Why?
|
| Phenazopyridine | 1 | 2018 | 6 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2017 | 377 | 0.130 |
Why?
|
| Renal Veins | 1 | 2017 | 8 | 0.130 |
Why?
|
| Phlebography | 1 | 2017 | 45 | 0.130 |
Why?
|
| Surgical Instruments | 1 | 2017 | 44 | 0.130 |
Why?
|
| Prostate | 1 | 2018 | 124 | 0.130 |
Why?
|
| Electrochemotherapy | 1 | 2017 | 1 | 0.130 |
Why?
|
| Prostate-Specific Antigen | 1 | 2017 | 84 | 0.130 |
Why?
|
| Printing, Three-Dimensional | 1 | 2017 | 42 | 0.130 |
Why?
|
| Intraoperative Complications | 1 | 2017 | 88 | 0.120 |
Why?
|
| Ergonomics | 1 | 2016 | 79 | 0.120 |
Why?
|
| Linear Models | 1 | 2017 | 405 | 0.120 |
Why?
|
| Diuretics | 1 | 2016 | 58 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2017 | 498 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2017 | 210 | 0.120 |
Why?
|
| Preoperative Care | 1 | 2017 | 199 | 0.110 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 552 | 0.110 |
Why?
|
| Ischemia | 1 | 2017 | 203 | 0.110 |
Why?
|
| Forecasting | 1 | 2016 | 230 | 0.110 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2016 | 128 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 931 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2017 | 755 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2017 | 310 | 0.110 |
Why?
|
| Contrast Media | 1 | 2017 | 432 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2492 | 0.100 |
Why?
|
| Patient Selection | 1 | 2017 | 484 | 0.100 |
Why?
|
| Curriculum | 1 | 2018 | 610 | 0.100 |
Why?
|
| Logistic Models | 1 | 2017 | 1273 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 741 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 708 | 0.090 |
Why?
|
| Quality of Life | 1 | 2017 | 1263 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 2776 | 0.070 |
Why?
|
| Animals | 3 | 2020 | 21390 | 0.070 |
Why?
|
| Equipment Design | 2 | 2018 | 371 | 0.060 |
Why?
|
| Young Adult | 1 | 2016 | 4838 | 0.060 |
Why?
|
| Administration, Intravenous | 1 | 2024 | 76 | 0.050 |
Why?
|
| Perfusion | 1 | 2023 | 76 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2023 | 146 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2022 | 744 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 529 | 0.040 |
Why?
|
| Polyethylene | 1 | 2018 | 11 | 0.040 |
Why?
|
| Silicones | 1 | 2018 | 14 | 0.040 |
Why?
|
| Chickens | 1 | 2018 | 94 | 0.040 |
Why?
|
| Urinary Bladder | 1 | 2018 | 48 | 0.040 |
Why?
|
| Laser Therapy | 1 | 2018 | 40 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2018 | 65 | 0.030 |
Why?
|
| Cadaver | 1 | 2018 | 134 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 106 | 0.030 |
Why?
|
| Burns, Electric | 1 | 2018 | 4 | 0.030 |
Why?
|
| Color | 1 | 2018 | 26 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2018 | 30 | 0.030 |
Why?
|
| Urine | 1 | 2018 | 47 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 296 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2017 | 69 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 2017 | 63 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 43 | 0.030 |
Why?
|
| Models, Animal | 1 | 2018 | 242 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2017 | 77 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2018 | 606 | 0.030 |
Why?
|
| Temperature | 1 | 2018 | 317 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 491 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 419 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 460 | 0.030 |
Why?
|
| Patient Safety | 1 | 2018 | 281 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 589 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2022 | 3325 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 1021 | 0.030 |
Why?
|
| Models, Biological | 1 | 2018 | 1192 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 3774 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 5649 | 0.020 |
Why?
|